Skip to content

to Evaluate the Glucose Lowering Effect of Jackfruit365â?¢ Meal in Patients with Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Glucose Lowering Effect of Jackfruit365â?¢ Meal in Patients with Type 2 Diabetes Mellitus

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/05/019417
Enrollment
40
Registered
2019-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Jack Fruit Flour, food product: 03 Scoops Jackfruit365 flour with morning meals and evening meals daily for a period of 12 weeks Control Intervention1: Placebo: 03 Scoops of Placebo wit

Sponsors

Diet Fibre TM food products private limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients in the age group of 18 to 60 years, both inclusive. 2. Patients suffering from Type II Diabetes Mellitus for more than one year, and stabilized on mono / poly oral hypoglycemic drug under anti-diabetic therapy. 3. Patients having HbA1c value below 8% at screening. 4. Patients of female gender or non-pregnant, non-lactating females. A urine pregnancy test is required for all female subjects of childbearing potential unless subject has had a hysterectomy, tubal ligation, or is > 2 years postmenopausal. 5. Patients who willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Type-I & Type-II Diabetic patients who are on Insulin. 2. Known cases of severe/chronic hepatic or renal disease. 3. Known patient of any active malignancy. 4. Patients giving history of significant cardiovascular event 5. Patients having history of known major complications of Diabetes like Ketoacidosis, Nephropathy, Neuropathy, Retinopathy, and Diabetic wounds. 6. Patients having history of known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 7. Known patients of having active metabolic or gastrointestinal diseases that may interfere with nutrient absorption, metabolism, or excretion, excluding diabetes. 8. Patients using any other investigational drug within 1 month prior to recruitment 9. Patients currently participating in any other clinical study 10. Any other condition due to which patients are deemed to be unsuitable by the investigator for reason(s) not specifically stated in the exclusion criteria

Design outcomes

Primary

MeasureTime frame
1. Evaluate changes in level of HbA1c after 12 weeks intake of Jack fruit 365 Green Jack fruit flour.Timepoint: 1. Evaluate changes in level of HbA1c after 12 weeks intake of Jack fruit 365 Green Jack fruit flour.

Secondary

MeasureTime frame
1. Evaluate the effect of Jack Fruit365TM by observing changes on FBG and PPG and lipid profile after 12 weeks intake of jack fruit 364TM Green Jack Fruit Flour. 2. Evaluate Changes in glucose level by continuous glucose monitoring for 2 weeks following intake of jack fruit365 green jack fruit flour in a subset from the baseline. 3. Evaluate changes in weight, body mass index after 12 week intake of Jack fruit365 Green Jackfruit Flour. Timepoint: baseline to 12 weeks

Countries

India

Contacts

Public ContactPawan bhusari

Diet Fibre 365 Food Products private limited

jamesjoseph@hotmail.com9740877566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 22, 2026